Insulin’s Out-Of-Pocket Cost Burden To Diabetic Patients Continues To Rise Despite Reduced Net Costs To PBMs

While net costs of insulin to PBMs and payers have decreased in recent years, owing to steep rebates, these savings have not necessarily been passed through to patients. Patients are either paying the full retail price if uninsured or in the deductible phase, or co-insurance based on the list price.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive